|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Depleting Cdh1 accelerates breast cancer cell proliferation and cooperates with PTEN loss to promote breast tumor progression in mice.
|
31420536 |
2019 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumors.
|
29610289 |
2018 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Breast neoplasms had the highest CDH1-mutation rate.
|
26674224 |
2016 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Profiling the predicted E-cadherin-targeting miRNAs in breast cancer tissues and cells showed that miR-221 was abundantly expressed in breast tumor and metastatic MDA-MB-231 cells and its level was significantly higher in breast tumor or MDA-MB-231 cells than in distal non-tumor tissue and low-metastatic MCF-7 cells, respectively.
|
27174021 |
2016 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
|
24014025 |
2013 |
|
Mammary Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.
|
24014025 |
2013 |
|
Mammary Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
|
23921149 |
2013 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
|
23921149 |
2013 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Loss of the wild-type CDH1 allele in 1 of the breast tumors was confirmed by LOH and IHC studies, in accordance with the "2-hit" model of tumor suppressor genes.
|
21271559 |
2011 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.
|
19839049 |
2010 |
|
Mammary Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.
|
19839049 |
2010 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.
|
18321996 |
2008 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Dissection of the APCCdh1-Skp2 cascade in breast cancer.
|
18381934 |
2008 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
|
17649807 |
2007 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Germline E-cadherin mutations in familial lobular breast cancer.
|
17660459 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro.
|
16932944 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma.
|
17520682 |
2007 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma.
|
17520682 |
2007 |
|
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.
|
16495925 |
2006 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this study we set out to determine CDH1 promoter methylation in breast tumors with decreased or absent E-cadherin protein expression and without CDH1 gene mutations by methylation-specific PCR (MSP).
|
15178462 |
2004 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Cytoplasmic p120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer.
|
15161659 |
2004 |
|
Mammary Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
In this study we set out to determine CDH1 promoter methylation in breast tumors with decreased or absent E-cadherin protein expression and without CDH1 gene mutations by methylation-specific PCR (MSP).
|
15178462 |
2004 |
|
Mammary Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability.
|
12800196 |
2003 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Recovery of cellular E-cadherin precedes replenishment of estrogen receptor and estrogen-dependent proliferation of breast cancer cells rescued from a death stimulus.
|
12115723 |
2002 |
|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
The SLUG zinc-finger protein represses E-cadherin in breast cancer.
|
11912130 |
2002 |